Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system

doi:/10.1016/j.nano.2018.01.010

CSMUIR > The College of Medical Sciences and Technology > School of medical imaging and radiological sciences > Periodical paper > Item 310902500/21008

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/21008

Title:	Assessing the selective therapeutic efficacy of superparamagnetic erlotinib nanoparticles in lung cancer by using quantitative magnetic resonance imaging and a nuclear factor kappa-B reporter gene system
Authors:	Fei-Ting Hsu;Hua-Shan Liu;Ahmed Atef Ahmed Ali;Ping-Huei Tsai;Yu-Chieh Kao;Chia-Feng Lu;Hsu-Shan Huang;Cheng-Yu Chen
Contributors:	醫學影像暨放射科學系
Keywords:	ErlotinibSuperparamagnetic iron oxideMagnetic resonance imagingNuclear factor-κBNon-small-cell lung cancer
Date:	2017-10-17
Issue Date:	2020-08-06T05:16:18Z (UTC)
Publisher:	Nanomedicine: Nanotechnology, Biology and Medicine
Abstract:	AbstractNon-small-cell lung cancer (NSCLC) is the most common type of lung cancer. Epidermal growth factor receptor (EGFR) tyrosine kinaseinhibitors are commonly used as the first-line treatment for advanced NSCLC; however, the efficacy of drug delivery remains unknown.Hence, we successfully developed erlotinib-conjugated iron oxide nanoparticles (FeDC-E NPs) as theranostic probe that can potentiallyprovide a new avenue for monitoring drug delivering through noninvasive magnetic resonance imaging. MRIΔR2* relaxivity measurementsoffer an opportunity to quantitatively evaluate the uptake of FeDC-E NPs at cellular and tumoral levels. Additionally, NF-κB reporter genesystem provides NF-κB activation status monitoring to validate the therapeutic efficiency of FeDC-E NPs. FeDC-E NPs not only inhibit thetumor growth and NF-κB-modulated antiapoptotic mechanism but also trigger extrinsic and intrinsic apoptotic pathways. Taken together,dual functional FeDC-E NPs offer diagnostic and therapeutic benefits against lung cancers, indicating that our presented probe could be applied in clinical.
URI:	https://ir.csmu.edu.tw:8080/ir/handle/310902500/21008
Relation:	Nanomedicine: Nanotechnology, Biology and Medicine Volume 14, Issue 3, April 2018, Pages 1019-1031
Appears in Collections:	[School of medical imaging and radiological sciences] Periodical paper

Files in This Item:

File	Description	Size	Format
4-main.pdf		3024Kb	Adobe PDF	272	View/Open

View Licence

Loading...